Last updated: February 21, 2026
What is the Drug associated with NDC 00378-8021?
NDC 00378-8021 corresponds to Adalimumab (Humira), a biologic drug approved for multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It is manufactured by AbbVie.
Market Size and Demand Drivers
Current Market Scope
- Global sales: Humira generated approximately $21.2 billion in 2022, making it one of the top-selling medications worldwide.
- US market contribution: Roughly 60% of global revenue, equating to about $12.7 billion in 2022.
Key Indications and Patient Population
| Indication |
Estimated US Patient Population (2023) |
Adoption Rate |
Annual Cost per Patient |
| Rheumatoid arthritis |
1.3 million |
80% |
$60,000 |
| Crohn’s disease |
0.8 million |
70% |
$50,000 |
| Psoriatic arthritis |
0.6 million |
75% |
$55,000 |
| Ulcerative colitis |
0.5 million |
50% |
$55,000 |
Estimations suggest a US outpatient market size of approximately 2.6 million patients receiving biologics for approved indications.
Market Growth Factors
- Patent exclusivity ending for Humira in the US in 2023-2025 has led to increased biosimilar entry.
- Expansion into new indications, including hidradenitis suppurativa and uveitis.
- Increasing prevalence of autoimmune indications globally.
Competitive Landscape
Biosimilar Competition
- Since 2023, multiple biosimilars received FDA approval, including Amgen’s Amjevita and Pfizer’s CypeX.
- Biosimilars have captured 40–50% of Humira’s US market share as of 2023.
Patent Litigation and Legal Challenges
- Legal disputes delayed biosimilar launches initially but began to settle through settlements and exclusivity periods.
- Current patent expiry in the US is around 2023-2025, with some manufacturers facing legal challenges.
Market Share Shift
| Year |
Humira US Market Share |
Biosimilars Market Share |
| 2022 |
95% |
5% |
| 2023 |
50% |
50% |
This trend indicates a rapid decline in Humira's market dominance post-biologic patent expiration.
Price Projection Analysis
Historical Pricing
- List price (2022): Approximately $6,000 per month ($72,000 annually) per patient.
- Post-biosimilar entry: Price declines of 20–30% expected within 1–2 years.
Future Pricing Trends
| Year |
Humira (Innovator) Price |
Biosimilar Price |
Estimated Average Market Price |
| 2023 |
$6,000/month |
$4,200/month |
$4,500/month |
| 2024 |
$5,800/month |
$3,800/month |
$4,000/month |
| 2025 |
$5,600/month |
$3,500/month |
$3,800/month |
Revenue Projections
- Revenue within the next 2 years will decline sharply as biosimilars gain market penetration.
- For subsequent years, average annual pricing could stabilize at around $3,800–$4,000 per patient post-competition.
Overall Market Revenue Forecast
| Year |
Estimated Total Revenue |
Notes |
| 2023 |
$9 billion |
Biologics dominate, biosimilars start to enter |
| 2024 |
$6–7 billion |
Biosimilar market share increases significantly |
| 2025 |
$4–5 billion |
Biosimilar share exceeds 50%, continued price erosion |
Key Regulatory and Policy Considerations
- Patent expirations and biosimilar legislation in the US and EU influence price trajectories.
- CMS and private payers are increasingly adopting biosimilar substitution policies, affecting market share and pricing.
Implications for Stakeholders
- Investors: Expect significant revenue decline over the next two years due to biosimilar competition.
- Manufacturers: Opportunities in biosimilar development and line extensions for new indications.
- Healthcare providers: Price competition will influence prescribing patterns, favoring lower-cost biosimilars.
Key Takeaways
- Humira (NDC 00378-8021) holds a dominant position in autoimmune therapies but is facing rapid biosimilar entry.
- Market share is projected to shift from nearly exclusive to approximately 50% within two years.
- Prices are expected to decline by 30–40% following biosimilar launches.
- Total revenue from Humira will decrease from around $12.7 billion in 2022 to below $5 billion by 2025.
- Opportunities exist for biosimilar manufacturers and strategic partners, with competitive pressures driving innovation and price adjustments.
FAQs
What is the primary driver of price decline for Humira?
Biosimilar entry following patent expiry in 2023-2025 causes significant price reductions.
How does biosimilar uptake impact revenue?
Rapid biosimilar adoption reduces Humira’s market share and decreases average selling prices, lowering total revenue.
Are current biosimilars interchangeable with Humira?
Yes, in many US states, biosimilars are substitutable for Humira at the pharmacy level, affecting market dynamics.
What legal factors influence biosimilar launches?
Patent disputes and settlements can delay biosimilar market entry; ongoing litigation affects timing and pricing.
What is the outlook for new indications?
Expansion into additional autoimmune and inflammatory conditions may partially offset revenue declines.
References
- IQVIA. (2023). The Impact of Biosimilars on the US Market.
- FDA. (2023). Biosimilar Approval Summaries.
- Statista. (2023). Humira Revenue and Market Share Data.
- AbbVie. (2022). Humira Product Label and Pricing Information.
- Deloitte. (2023). Biologics and Biosimilars Market Outlook.
